triiodothyronine has been researched along with gemcitabine in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Brunetti, E; Bucci, B; Michienzi, S; Misiti, S; Panacchia, L; Patriarca, V; Stigliano, A; Toscano, V; Verga Falzacappa, C | 1 |
1 review(s) available for triiodothyronine and gemcitabine
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 other study(ies) available for triiodothyronine and gemcitabine
Article | Year |
---|---|
3,3',5-Triiodo-L-thyronine inhibits ductal pancreatic adenocarcinoma proliferation improving the cytotoxic effect of chemotherapy.
Topics: Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Carcinoma, Pancreatic Ductal; Cell Cycle; Cell Line, Tumor; Cell Proliferation; Cisplatin; Cyclin D1; Cyclin D2; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Deoxycytidine; Drug Synergism; Electrophoresis, Polyacrylamide Gel; Flow Cytometry; Fluorouracil; Gemcitabine; Humans; p21-Activated Kinases; Pancreatic Neoplasms; Protein Serine-Threonine Kinases; Receptors, Thyroid Hormone; Triiodothyronine | 2007 |